Hims & Hers HealthHIMS
HIMS
About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Employees: 1,637
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
56% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 72
50% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 9 (+3) [Q1 2025]
17% more capital invested
Capital invested by funds: $3.97B [Q4 2024] → $4.63B (+$657M) [Q1 2025]
7% more funds holding
Funds holding: 390 [Q4 2024] → 418 (+28) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 141
4.96% less ownership
Funds ownership: 78.16% [Q4 2024] → 73.2% (-4.96%) [Q1 2025]
21% less call options, than puts
Call options by funds: $486M | Put options by funds: $618M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$26
53%
downside
Avg. target
$38
32%
downside
High target
$65
17%
upside
7 analyst ratings
1 positive
14%
4 neutral
57%
2 negative
29%
Morgan Stanley Craig Hettenbach | 28%downside $40 | Equal-Weight Reiterated | 11 Jun 2025 |
Needham Ryan MacDonald | 17%upside $65 | Buy Maintained | 4 Jun 2025 |
Piper Sandler Korinne Wolfmeyer | 30%downside $39 | Neutral Reiterated | 6 May 2025 |
Citigroup Daniel Grosslight | 46%downside $30 | Sell Maintained | 6 May 2025 |
B of A Securities Allen Lutz | 53%downside $26 | Underperform Maintained | 29 Apr 2025 |
Financial journalist opinion
Based on 56 articles about HIMS published over the past 30 days
Positive
Seeking Alpha
9 hours ago
Hims & Hers: An Excellent Subscription Business
Hims & Hers offers a high-growth, recurring subscription telehealth business with strong user and revenue growth, expanding into multiple health segments. It is the market leader in telehealth easily outpacing its competition. The trend among millenials and Gen Z patients towards digital health should ensure Hims sustaining its pole position.
Positive
Zacks Investment Research
1 day ago
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Neutral
Schaeffers Research
2 days ago
These 24 Stocks Are Ripe for a Short Squeeze
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
Neutral
Zacks Investment Research
2 days ago
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
Positive
Seeking Alpha
4 days ago
Hims & Hers: The ZAVA Acquisition Catapults Growth In Europe's Weight-Loss Market
Hims & Hers Health's acquisition of ZAVA fast-tracks its entry into Europe's weight-loss market, expanding its subscriber base by 54%. The deal is attractively priced, non-dilutive, and leverages ZAVA's established infrastructure and regulatory expertise across four major European countries. Hims' proven GLP-1 strategy in the U.S. positions it to address Europe's unmet demand for affordable, personalized weight-loss solutions via telehealth.
Negative
Zacks Investment Research
4 days ago
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.
Positive
24/7 Wall Street
4 days ago
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLO – Is it Time to Sell?
Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it's not for the faint of heart.
Positive
Reuters
4 days ago
Hims & Hers says its weight-loss business can grow as US market changes
Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing competition in the U.S.
Positive
Zacks Investment Research
5 days ago
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Positive
The Motley Fool
6 days ago
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (HIMS 6.96%) may finally be succeeding in cracking the code.
Charts implemented using Lightweight Charts™